000650 仁和药业
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,975,091-16.46%4,074,8935,032,1465,153,2154,935,755
减:营业总成本1,609,100-16.01%3,362,2324,045,0634,208,2373,952,008
    其中:营业成本1,252,353-14.07%2,528,8813,164,0923,266,2773,061,415
               财务费用170-101.94%(10,312)(24,925)(23,065)(55,244)
               资产减值损失100-124.99%(113,320)(223,111)(68,739)(5,066)
公允价值变动收益39-104.12%16,03416,82822,115(26)
投资收益26,729186.06%72,70259,26146,31431,475
    其中:对联营企业和合营企业的投资收益(1,774)-10.22%(4,831)(915)1,8036
营业利润461,637-15.24%774,986898,635953,2631,036,928
利润总额461,150-14.87%774,618898,860953,5401,034,418
减:所得税费用105,910-17.90%208,033269,450241,997234,545
净利润355,241-13.92%566,586629,410711,542799,874
减:非控股权益64,815-14.19%84,67462,153137,112134,849
股东净利润290,426-13.87%481,912567,257574,430665,025

市场价值指针
每股收益 (元) *0.208-13.86%0.3500.4100.4100.480
每股派息 (元) *----0.1500.2000.2000.100
每股净资产 (元) *4.475-0.44%4.4104.2814.1013.777
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容